The Latin America, Middle East and Africa Biochips Market would witness market growth of 12.3% CAGR during the forecast period (2019-2025).
In the field of biomedical and biotechnological studies, biochips are becoming increasingly used. As the technology in the sector of medicine progresses, the use of proteomics biochips such as microarrays has been increasing. Low sample consumption and their inclination to miniaturization include the benefits of protein biochips. For example, protein microarrays can simultaneously display multiple proteins, which translate into the ability to process thousands of samples in parallel. For a proteome-wide assessment, this feature of microarrays is essential.
Biomarker and drug discovery are commonly used in proteomics. In addition, the surge in the requirement for personalized disease medicine helps the industry grow. The biochip market is being largely influenced by factors such as increased use of biochips in the treatment and diagnosis of cancer and demand for personally tailored medicine, and rapid technological progress.
Based on Product, the market is segmented into DNA Chip, Protein Chip, Lab-on-Chip and Other Products. Based on Application, the market is segmented into Drug Discovery and Development, Disease Diagnostics, Genomics, Proteomics, Agriculture and Other Applications. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Fluidigm Corporation, Horiba Ltd., PerkinElmer, Inc., OriGene Technologies, Inc., Dynamic Biosensors GmbH, Illumina, Inc., Qiagen N.V., Bio-Rad Laboratories, Inc., Randox Laboratories Limited, Thermo Fisher Scientific, Inc.
Market Segmentation:
ByProduct
By Application
By End User
By Country
Companies Profiled
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
